Researchers sought to determine whether the ALL-Hematotox would be able to predict hematotoxicity for patients with B-ALL who are at risk of severe hematotoxicity following CAR-T therapy.

If approved, ziftomenib could be the first FDA-approved Menin inhibitor for relapsed/refractory acute myeloid leukemia with ...

Fifty-two cancer survivors and their families came together in the East Valley to celebrate the strength and resilience of pediatric cancer patients.

TURKU, FI / ACCESS Newswire / May 30, 2025 / Faron Pharmaceuticals (HEL:FARON)(LSE:FARN) - Phase I study shows promising clinical activity and tolerability of bexmarilimab plus standard-of-care in ...

Don't dismiss persistent fatigue and bruising. These 11 warning signs could indicate acute myelogenous leukemia hiding in ...

Learn about acute myelogenous leukemia (AML), its sneaky symptoms, aggressive nature, and how bone marrow produces defective ...

Medically reviewed by Archana Sharma, DO Acute myelogenous leukemia (AML), also known as acute myeloid leukemia, is a type of ...

Using the National Cancer Database, this retrospective cohort study identified 23,397 ALL patients between the ages of 0-18 who received chemotherapy from 2004-2020. Patients with race listed as ...

An international study has uncovered why a widely used treatment for acute myeloid leukemia (AML) doesn't work for everyone. The findings could help doctors better match patients with the therapies ...

An international study led by the University of Colorado Cancer Center has uncovered why a widely used treatment for acute ...

A combination of two drugs could improve outcomes and reduce the need for toxic chemotherapy for B-cell acute lymphoblastic leukemia (B ... new treatments have begun to emerge, including bone marrow ...